neratinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 5252 698387-09-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • neratinib
  • neratinib maleate
  • HKI-272
  • nerlynx
Neratinib is a kinase inhibitor that irreversibly binds to Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and HER4. In vitro, neratinib reduces EGFR and HER2 autophosphorylation, downstream MAPK and AKT signaling pathways, and showed antitumor activity in EGFR and/or HER2 expressing carcinoma cell lines. Neratinib human metabolites M3, M6, M7 and M11 inhibited the activity of EGFR, HER2 and HER4 in vitro. In vivo, oral administration of neratinib inhibited tumor growth in mouse xenograft models with tumor cell lines expressing HER2 and EGFR.
  • Molecular weight: 557.05
  • Formula: C30H29ClN6O3
  • CLOGP: 5
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 2
  • TPSA: 112.40
  • ALOGS: -4.92
  • ROTB: 11
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.24 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Aug. 8, 2018 EMA PUMA BIOTECH INC
July 17, 2017 FDA PUMA BIOTECH INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 130.37 60.34 141 2090 715225 62771566
Disease progression 124.76 60.34 68 2163 122690 63364101
Ejection fraction decreased 98.97 60.34 35 2196 22297 63464494
Neuropathy peripheral 93.82 60.34 55 2176 113612 63373179
Hyperchlorhydria 89.08 60.34 19 2212 1825 63484966
Folate deficiency 83.51 60.34 19 2212 2456 63484335
Off label use 76.51 60.34 105 2126 674357 62812434
Lacrimation increased 67.94 60.34 26 2205 20605 63466186
Nail dystrophy 63.40 60.34 13 2218 1030 63485761
Odynophagia 62.66 60.34 19 2212 7467 63479324

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 120.92 63.75 129 1922 880360 78861977
Disease progression 108.17 63.75 64 1987 184298 79558039
Neuropathy peripheral 95.98 63.75 54 1997 141251 79601086
Ejection fraction decreased 94.72 63.75 35 2016 34542 79707795
Hyperchlorhydria 86.87 63.75 18 2033 2061 79740276
Folate deficiency 78.27 63.75 18 2033 3342 79738995
Lacrimation increased 73.70 63.75 26 2025 22451 79719886
Nail dystrophy 67.83 63.75 13 2038 1000 79741337

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EH02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
FDA MoA N0000175082 Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000185503 P-Glycoprotein Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
HER2-positive carcinoma of breast indication 427685000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.4 acidic
pKa2 8.94 Basic
pKa3 6.11 Basic
pKa4 3.66 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 7982043 Oct. 8, 2025 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 7982043 Oct. 8, 2025 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 7982043 Oct. 8, 2025 USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 10035788 Oct. 15, 2028 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 10035788 Oct. 15, 2028 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 10035788 Oct. 15, 2028 USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 9139558 Oct. 15, 2028 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 9139558 Oct. 15, 2028 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 9139558 Oct. 15, 2028 USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 9630946 Oct. 15, 2028 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 9630946 Oct. 15, 2028 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 9630946 Oct. 15, 2028 USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 9265784 Aug. 4, 2029 USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 9211291 March 24, 2030 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 9211291 March 24, 2030 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 8790708 Nov. 5, 2030 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 8790708 Nov. 5, 2030 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 8790708 Nov. 5, 2030 USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 8518446 Nov. 20, 2030 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 8518446 Nov. 20, 2030 EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 8518446 Nov. 20, 2030 USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL 8669273 July 18, 2031 USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL Feb. 25, 2023 USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
EQ 40MG BASE NERLYNX PUMA BIOTECH N208051 July 17, 2017 RX TABLET ORAL June 28, 2024 NEW DOSING REGIMEN FOR THE PREVENTION AND MANAGEMENT OF NERATINIB‐ASSOCIATED DIARRHEA

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Receptor tyrosine-protein kinase erbB-4 Kinase INHIBITOR Kd 8.62 SCIENTIFIC LITERATURE DRUG LABEL
Epidermal growth factor receptor Kinase INHIBITOR IC50 7.04 SCIENTIFIC LITERATURE DRUG LABEL
Receptor tyrosine-protein kinase erbB-2 Kinase INHIBITOR IC50 7.23 SCIENTIFIC LITERATURE DRUG LABEL
Tyrosine-protein kinase ABL1 Kinase Kd 5.22 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 5.39 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 6.92 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 6.62 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.19 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 5.51 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 6.07 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 6.17 CHEMBL
Insulin receptor Kinase Kd 5.52 CHEMBL
Mitogen-activated protein kinase 8 Kinase Kd 5.48 CHEMBL
Focal adhesion kinase 1 Kinase Kd 5.72 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 6.31 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.60 CHEMBL
Tyrosine-protein kinase SYK Kinase Kd 5.29 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 6.26 CHEMBL
Angiopoietin-1 receptor Kinase Kd 5.52 CHEMBL
Hepatocyte growth factor receptor Kinase Kd 5.40 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.09 CHEMBL
Serine/threonine-protein kinase Nek2 Kinase Kd 6.60 CHEMBL
Ribosomal protein S6 kinase alpha-2 Kinase Kd 5.39 CHEMBL
Serine/threonine-protein kinase 17B Kinase Kd 5.96 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 7.89 CHEMBL
Tyrosine-protein kinase Fer Kinase Kd 6.29 CHEMBL
Serine/threonine-protein kinase 17A Kinase Kd 6.47 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 6.85 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 6.54 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 5.72 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 5.28 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 9.19 CHEMBL
Cyclin-G-associated kinase Kinase Kd 6.60 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D Kinase Kd 5.25 CHEMBL
Cyclin-dependent kinase 16 Kinase Kd 5.64 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 6.57 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 6.17 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 7.18 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 7 Kinase Kd 6.28 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 7.85 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 7.59 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 6.80 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 6.72 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 5.29 CHEMBL
Serine/threonine-protein kinase D1 Kinase Kd 6.09 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 7.24 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase Chk1 Kinase Kd 5.24 CHEMBL
Wee1-like protein kinase Kinase Kd 5.39 CHEMBL
Serine/threonine-protein kinase 25 Kinase Kd 7.92 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 5.82 CHEMBL
Protein-tyrosine kinase 2-beta Kinase Kd 5.10 CHEMBL
Casein kinase I isoform gamma-2 Kinase Kd 5.18 CHEMBL
Casein kinase I isoform gamma-3 Kinase Kd 5.11 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 6.41 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 5.32 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 5.80 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 8.13 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 7.02 CHEMBL
Insulin receptor-related protein Kinase Kd 5.34 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 5.48 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 6.03 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 7.03 CHEMBL
Serine/threonine-protein kinase PAK 6 Kinase Kd 5.13 CHEMBL
NUAK family SNF1-like kinase 1 Kinase Kd 5.82 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 8.11 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 7.07 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 6.48 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 6.40 CHEMBL
Mitogen-activated protein kinase kinase kinase 9 Kinase Kd 5.27 CHEMBL
Mitogen-activated protein kinase kinase kinase 10 Kinase Kd 5.34 CHEMBL
Mitogen-activated protein kinase kinase kinase 11 Kinase Kd 5.24 CHEMBL
Serine/threonine-protein kinase 24 Kinase Kd 8.19 CHEMBL
Serine/threonine-protein kinase PAK 1 Kinase Kd 6.68 CHEMBL
Serine/threonine-protein kinase PAK 2 Kinase Kd 7.10 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 6.66 CHEMBL
Serine/threonine-protein kinase D2 Kinase Kd 5.96 CHEMBL
Serine/threonine-protein kinase D3 Kinase Kd 5.62 CHEMBL
Tyrosine-protein kinase Fes/Fps Kinase Kd 6.23 CHEMBL
Ribosomal protein S6 kinase alpha-1 Kinase Kd 5.13 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 6.66 CHEMBL
Misshapen-like kinase 1 Kinase Kd 7.54 CHEMBL
Serine/threonine-protein kinase Chk2 Kinase Kd 6.07 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 5.55 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 5.82 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 5.64 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 6.13 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 6.35 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 6.89 CHEMBL
Microtubule-associated serine/threonine-protein kinase 1 Kinase Kd 5.26 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 5.38 CHEMBL
Mitogen-activated protein kinase kinase kinase 4 Kinase Kd 7.41 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 5.35 CHEMBL
Receptor tyrosine-protein kinase erbB-3 Kinase Kd 8.11 CHEMBL
Wee1-like protein kinase 2 Kinase Kd 5.89 CHEMBL
Serine/threonine-protein kinase Nek3 Kinase Kd 5.62 CHEMBL
Mitogen-activated protein kinase kinase kinase 12 Kinase Kd 6.43 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 7.20 CHEMBL
Dual serine/threonine and tyrosine protein kinase Kinase Kd 5.19 CHEMBL
Serine/threonine-protein kinase 32B Kinase Kd 5.19 CHEMBL
Ferrochelatase, mitochondrial Enzyme Kd 5.22 CHEMBL
Uncharacterized aarF domain-containing protein kinase 5 Kinase Kd 6.10 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7.80 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.70 CHEMBL
Macrophage-stimulating protein receptor Kinase Kd 5.08 CHEMBL

External reference:

IDSource
JJH94R3PWB UNII
4036844 VANDF
C2713008 UMLSCUI
CHEBI:61397 CHEBI
CHEMBL180022 ChEMBL_ID
9915743 PUBCHEM_CID
DB11828 DRUGBANK_ID
D08950 KEGG_DRUG
CHEMBL3989921 ChEMBL_ID
8878 INN_ID
5686 IUPHAR_LIGAND_ID
260081 MMSL
32930 MMSL
d08621 MMSL
017280 NDDF
017281 NDDF
736632003 SNOMEDCT_US
736633008 SNOMEDCT_US
763563007 SNOMEDCT_US
915942-22-2 SECONDARY_CAS_RN
1940642 RXNORM
C487932 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None